A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-004278-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine 6 months progression-free survival of the combination of doxorubicin, cyclophosphamide and vindesine (VdsAC) plus valproic acid in patients with refractory SCLC after treatment with platinum derivatives, cisplatin or carboplatin, and etoposide.


Critère d'inclusion

  • This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of refractory or recurrent small cell lung carcinoma after platinum derivatives and etoposide, for which no standard treatment is available in this indication

Liens